New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 28, 2018 - The FDA announced the permanent discontinuation of AstraZeneca’s Lynparza (olaparib) 50 mg capsules.
Download PDF
Return to publications
